Canada Markets closed
  • S&P/TSX

    -206.31 (-1.19%)
  • S&P 500

    -16.72 (-0.46%)
  • DOW

    -271.73 (-0.91%)

    +0.0015 (+0.1950%)

    -0.41 (-0.90%)

    +75.48 (+0.30%)
  • CMC Crypto 200

    +19.93 (+5.47%)

    +5.20 (+0.29%)
  • RUSSELL 2000

    -35.45 (-1.91%)
  • 10-Yr Bond

    +0.0020 (+0.24%)
  • NASDAQ futures

    +104.75 (+0.85%)

    -0.27 (-1.30%)
  • FTSE

    -101.39 (-1.59%)
  • NIKKEI 225

    +390.84 (+1.48%)

    0.0000 (0.00%)

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

·3 min read

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing

-Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs

Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Allogeneic Cell Therapies Summit. The Conference, which will be held as a virtual event on October 26-28, is focused on the clinical and commercial development of engineered allogeneic cell therapies with improved manufacturing and commercialization to benefit patients in need.

Vycellix Presentation Details:


Allogeneic Cell Therapies Summit (virtual conference)


Evren Alici, M.D., Ph.D., Chairman & CEO, Vycellix, Inc.


Wednesday, October 28 at 12pm ET


Manufacturing Track


Scaling Up & Scaling Out NK Cell Based Products for Clinical Use


Dr. Alici’s presentation will include discussion reporting on Vycellix’s VY-UC platform, designed to generate immune-privileged universal cells without altering the components that control self-recognition (HLA). Cells modified by VY-UC avoid immune recognition of grafted cells without impacting HLA while conserving viability, functionality, and persistence. The Company has achieved proof-of-concept for VY-UC in a range of effector cell-based immunotherapies including T cells, CAR-T and NK cells.

Dr. Alici is group leader in Hematology at Karolinska Institutet (KI), Department of Medicine, Stockholm, Sweden. He also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI.

For more information, please visit: and follow our Twitter feed at: @Vycellix.

About Vycellix™, Inc.

Vycellix is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies.

Forward Looking Statements:

This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as "plan," "expect," "anticipate," "may," "might," "will," "should," "project," "believe," "estimate," "predict," "potential," "intend," or "continue" and other words or terms of similar meaning. These statements include, without limitation, statements related to the pre-clinical, regulatory, clinical and/or commercial development and all anticipated uses of VY-OZ, VY-X, VY-M and VY-UC, and the Company’s plans for seeking out-licensing opportunities for these assets. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with immuno-discovery product development, including risks associated with advancing products to human clinical trials and/or ultimately regulatory and commercial success which is subject to the uncertainty of regulatory approval, market adoption and other risks and uncertainties affecting Vycellix and its development programs. Other risks and uncertainties of which Vycellix is not currently aware may also affect Vycellix’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. Vycellix undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

View source version on


Vycellix Corporate Contact:
Douglas W. Calder, President
Phone: (772)-418-6302